J&J biliary stent recall
This article was originally published in The Gray Sheet
Executive Summary
Cordis initiates Class I recall of recently revised instructions for its Precise RX biliary stent following 16 reports of adverse events and/or stent malfunctions related to off-label use in the peripheral vasculature, resulting in nine patient injuries including coma and seizure, the company reports May 7. "We regret our initial communication did not more strongly reinforce against off-label use," Dennis Donohoe, MD, Cordis VP-regulatory and clinical affairs, says in a release. The revised instructions were part of a Cordis Medical Device Notification sent to endovascular customers March 29 without FDA clearance. A May 4 follow-up notification describes the adverse events...
You may also be interested in...
Off-Label Practices Plague Circulatory System Device Randomized Trials
Off-label use of biliary stents is hindering superficial femoral artery (SFA) device development, CDRH Division of Cardiovascular Devices Director Bram Zuckerman told participants at CRT 2004 in Washington, D.C
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.